nicht kleckern ..klotzen ::POZEN
| eröffnet am: | 22.07.13 11:52 von: | buran |
| neuester Beitrag: | 25.04.21 13:11 von: | Sabinedhcua |
| Anzahl Beiträge: | 108 | |
| Leser gesamt: | 25000 | |
| davon Heute: | 3 | |
bewertet mit 1 Stern |
||
|
3
|
||
13.01.14 13:24
#51
buran
Nasdaq Glitzer Palast
Datum Erster Hoch Tief Schluss Stücke Volumen
10.01.14 8,22 8,25§8,13 8,24 $ 248.139 1,97 M
GrB
10.01.14 8,22 8,25§8,13 8,24 $ 248.139 1,97 M
GrB
20.01.14 15:20
#52
buran
grüner SK im Nasdaq Satz 17
Datum Erster Hoch Tief Schluss Stücke Volumen
17.01.14 8,64 8,91§8,64 8,80 $ 259.360 2,21 M
GrB
17.01.14 8,64 8,91§8,64 8,80 $ 259.360 2,21 M
GrB
20.01.14 15:21
#53
buran
17er Frankfurter dito
Datum Erster Hoch Tief Schluss Stücke Volumen
20.01.14 6,37 6,37§6,37 6,37 € * 0 0
17.01.14 6,209 6,448§6,209 6,448 € 50 322
GrB
20.01.14 6,37 6,37§6,37 6,37 € * 0 0
17.01.14 6,209 6,448§6,209 6,448 € 50 322
GrB
20.01.14 15:22
#54
buran
thread update
RTK 6,37 € RTP -1,21 Pott +55,06% buran und MfG und schüddelbööööön
06.03.14 19:48
#55
buran
174 Tausend geeeeeeeeSCHMETTERT realtime
Bucheinsicht http://www.ariva.de/pozen-aktie/times_and_sales?boerse_id=40 GrB
06.03.14 19:50
#56
buran
und weiter weiter immer weiter ask RT
Preis pro share 8,18 $ Schleife 100 spread 0,37% buran und MfG und FREIHEIT FÜR NELSON MANDELA ..::hopshopshopshopshopshops
10.04.14 08:30
#57
buran
POZN 09-04 Nasdaq
Datum Erster Hoch Tief Schluss Stücke Volumen
09.04.14 8,61 8,8065§8,60 8,73 $ 503.031 4,38 M
GrB
09.04.14 8,61 8,8065§8,60 8,73 $ 503.031 4,38 M
GrB
30.05.14 23:06
#60
buran
POZEN Announces May 8th Webcast of First Quarter
2014 Results
07:49 02.05.14
CHAPEL HILL, N.C. --(BUSINESS WIRE)--
POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2014 results on May 8, 2014, before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The first quarter 2014 earnings release will be accessible in the Media section of POZEN’s website.
About POZEN
POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these milestones/royalty streams, POZEN is creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
POZEN is currently seeking ex-U.S. strategic partners to help maximize the opportunities for its portfolio assets.
The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.http://www.ariva.de/news/...ast-of-First-Quarter-2014-Results-5021354
07:49 02.05.14
CHAPEL HILL, N.C. --(BUSINESS WIRE)--
POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2014 results on May 8, 2014, before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The first quarter 2014 earnings release will be accessible in the Media section of POZEN’s website.
About POZEN
POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these milestones/royalty streams, POZEN is creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
POZEN is currently seeking ex-U.S. strategic partners to help maximize the opportunities for its portfolio assets.
The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.http://www.ariva.de/news/...ast-of-First-Quarter-2014-Results-5021354
08.08.14 13:41
#61
buran
POZEN Resubmits PA8140/PA32540 NDA
22:05 01.07.14
CHAPEL HILL, N.C. --(BUSINESS WIRE)--
POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it has resubmitted the New Drug Application (NDA) for PA8140/PA32540 to the U.S. Food and Drug Administration (FDA). In accordance with the regulations, FDA is expected to notify POZEN within 14 days of receipt of the NDA whether or not the submission will be accepted, and if accepted, what the new PDUFA date will be. The FDA will determine whether a two month or six month review is necessary. Issues raised during an audit of the manufacturing facility producing an active ingredient used in the manufacture of the products were the only deficiencies noted in the Complete Response Letter (CRL) POZEN received on April 25, 2014. Final agreement on the draft product labeling is also pending.
“Our API supplier has been working to respond to the observations contained in the FDA inspector’s report. We recently completed our own onsite audit, and we understand that the supplier has now submitted a supplement to its May 9, 2014 initial response to the FDA,” said John Plachetka, chairman, president and CEO. “Based upon the available information, we believe there are actions in place that address the deficiencies noted by FDA.”
About POZEN
POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
POZEN is currently seeking strategic partners to help maximize the opportunities for its portfolio assets.
The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.
About PA
POZEN has created a portfolio of investigational integrated aspirin therapies - the PA product platform. The products in the PA portfolio are being developed with the goal of significantly reducing GI ulcers and other GI complications compared to taking enteric-coated or plain aspirin alone.
The first candidates are PA8140, containing 81 mg of aspirin, and PA32540, containing 325 mg of aspirin. Both products are a coordinated-delivery tablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor, layered around a pH-sensitive coating of an aspirin core. This novel, patented product is intended for oral administration once a day and an indication is being sought for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
Proposed PA Indications and Usage (Pending FDA Review and Approval)
PA8140/PA32540 Tablets contain 81 mg or 325 mg delayed release aspirin and 40 mg immediate-release omeprazole and are indicated for patients who require aspirin (1) to reduce the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, (2) to reduce the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, (3) to reduce the combined risk of MI and sudden death in patients with chronic stable angina pectoris, (4) in patients who have undergone revascularization procedures (CABG, PTCA) when there is a pre-existing condition for which aspirin is already indicated, and to decrease the risk of developing gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers.
Controlled studies with PA8140/PA32540 Tablets do not extend beyond 6 months.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results, our ability to return value to our stockholders, including any cash distributions, and our future prospects could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to further license our PA product candidates on terms and timing acceptable to us, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of our product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®, our dependence on Sanofi US for the sales and marketing of PA8140/PA32540 in the United States, if approved, and our dependence on Patheon for the manufacture of PA8140/PA32540; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended March 31, 2014. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.http://www.ariva.de/news/POZEN-Resubmits-PA8140-PA32540-NDA-5087927
CHAPEL HILL, N.C. --(BUSINESS WIRE)--
POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it has resubmitted the New Drug Application (NDA) for PA8140/PA32540 to the U.S. Food and Drug Administration (FDA). In accordance with the regulations, FDA is expected to notify POZEN within 14 days of receipt of the NDA whether or not the submission will be accepted, and if accepted, what the new PDUFA date will be. The FDA will determine whether a two month or six month review is necessary. Issues raised during an audit of the manufacturing facility producing an active ingredient used in the manufacture of the products were the only deficiencies noted in the Complete Response Letter (CRL) POZEN received on April 25, 2014. Final agreement on the draft product labeling is also pending.
“Our API supplier has been working to respond to the observations contained in the FDA inspector’s report. We recently completed our own onsite audit, and we understand that the supplier has now submitted a supplement to its May 9, 2014 initial response to the FDA,” said John Plachetka, chairman, president and CEO. “Based upon the available information, we believe there are actions in place that address the deficiencies noted by FDA.”
About POZEN
POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
POZEN is currently seeking strategic partners to help maximize the opportunities for its portfolio assets.
The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.
About PA
POZEN has created a portfolio of investigational integrated aspirin therapies - the PA product platform. The products in the PA portfolio are being developed with the goal of significantly reducing GI ulcers and other GI complications compared to taking enteric-coated or plain aspirin alone.
The first candidates are PA8140, containing 81 mg of aspirin, and PA32540, containing 325 mg of aspirin. Both products are a coordinated-delivery tablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor, layered around a pH-sensitive coating of an aspirin core. This novel, patented product is intended for oral administration once a day and an indication is being sought for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
Proposed PA Indications and Usage (Pending FDA Review and Approval)
PA8140/PA32540 Tablets contain 81 mg or 325 mg delayed release aspirin and 40 mg immediate-release omeprazole and are indicated for patients who require aspirin (1) to reduce the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, (2) to reduce the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, (3) to reduce the combined risk of MI and sudden death in patients with chronic stable angina pectoris, (4) in patients who have undergone revascularization procedures (CABG, PTCA) when there is a pre-existing condition for which aspirin is already indicated, and to decrease the risk of developing gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers.
Controlled studies with PA8140/PA32540 Tablets do not extend beyond 6 months.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results, our ability to return value to our stockholders, including any cash distributions, and our future prospects could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to further license our PA product candidates on terms and timing acceptable to us, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of our product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®, our dependence on Sanofi US for the sales and marketing of PA8140/PA32540 in the United States, if approved, and our dependence on Patheon for the manufacture of PA8140/PA32540; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended March 31, 2014. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.http://www.ariva.de/news/POZEN-Resubmits-PA8140-PA32540-NDA-5087927
08.08.14 13:42
#62
buran
CHAPEL HILL, N.C. --(BUSINESS WIRE)--
POZEN Announces August 7th Webcast of Second Quarter 2014 Results
22:05 24.07.14
CHAPEL HILL, N.C. --(BUSINESS WIRE)--
POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release second quarter 2014 results on August 7, 2014, before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The second quarter 2014 earnings release will be accessible in the Media section of POZEN’s website.
About POZEN
POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
POZEN is currently seeking strategic partners to help maximize the opportunities for its portfolio assets.
The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.http://www.ariva.de/news/...st-of-Second-Quarter-2014-Results-5111371
22:05 24.07.14
CHAPEL HILL, N.C. --(BUSINESS WIRE)--
POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release second quarter 2014 results on August 7, 2014, before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The second quarter 2014 earnings release will be accessible in the Media section of POZEN’s website.
About POZEN
POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
POZEN is currently seeking strategic partners to help maximize the opportunities for its portfolio assets.
The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.http://www.ariva.de/news/...st-of-Second-Quarter-2014-Results-5111371
26.10.14 11:28
#64
buran
schöne 8,75er Halte im Tickersatz 24-10 TOP
Datum Erster Hoch Tief Schluss Stücke Volumen
24.10.14 8,78 8,94§8,69 8,75 $ 256.474 2,25 M
GrB
24.10.14 8,78 8,94§8,69 8,75 $ 256.474 2,25 M
GrB
04.11.14 10:41
#65
buran
Mario Meierhof 29. September um 21:38.
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
04.11.14 10:41
#66
buran
#65
buran: auch ich war im Erziehungsheim lange eine Ewigkeit 228.10.14 20:01 #1
Mario Meierhof
29. September um 21:38 ·
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
http://www.ariva.de/forum/...rziehungsheim-lange-eine-Ewigkeit-510117
Mario Meierhof
29. September um 21:38 ·
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
http://www.ariva.de/forum/...rziehungsheim-lange-eine-Ewigkeit-510117
04.11.14 10:42
#67
buran
Kontakt
buran: Kontakt 01.10.14 21:33 #1 Inhalt
Haben Sie Fragen oder Anmerkungen?
Dann nutzen Sie unser Kontaktformular, um uns eine Nachricht zukommen zu lassen.
Als Medienvertreter nutzen Sie bitte die Seite cvd.bundesregierung.de.
Felder mit einem * sind Pflichtfelder und müssen ausgefüllt werden.
Selbstverständlich beachten wir die Vorschriften des Datenschutzes.
Hier geht es zur Datenschutzerklärung.
Betreff * Hallo ,vielleicht sowas mal unterbinden wäre nett
Ihre Anregungen und Fragen (max. 10.000 Zeichen) *noch 9663 Zeichen nur ein börsenboard geführt von www.bundesbank.de
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/forum/...rd-gefuehrt-von-www-bundesbank-de-508523
Vor- und Zuname * Mario Meierhof
E-Mail *mariomeierhof@web.de
Straße und Hausnummer Gartenstrasse 6
Postleitzahl 39517
Ort Lüderitz
* Pflichtangabe
https://www.bundesregierung.de/Webs/Breg/DE/.../kontaktform_node.html
Mit freundlichen Grüssen Mario Meierhof alias buran
http://www.ariva.de/forum/Kontakt-508620?new_pnr=18779196#bottom
Haben Sie Fragen oder Anmerkungen?
Dann nutzen Sie unser Kontaktformular, um uns eine Nachricht zukommen zu lassen.
Als Medienvertreter nutzen Sie bitte die Seite cvd.bundesregierung.de.
Felder mit einem * sind Pflichtfelder und müssen ausgefüllt werden.
Selbstverständlich beachten wir die Vorschriften des Datenschutzes.
Hier geht es zur Datenschutzerklärung.
Betreff * Hallo ,vielleicht sowas mal unterbinden wäre nett
Ihre Anregungen und Fragen (max. 10.000 Zeichen) *noch 9663 Zeichen nur ein börsenboard geführt von www.bundesbank.de
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/forum/...rd-gefuehrt-von-www-bundesbank-de-508523
Vor- und Zuname * Mario Meierhof
E-Mail *mariomeierhof@web.de
Straße und Hausnummer Gartenstrasse 6
Postleitzahl 39517
Ort Lüderitz
* Pflichtangabe
https://www.bundesregierung.de/Webs/Breg/DE/.../kontaktform_node.html
Mit freundlichen Grüssen Mario Meierhof alias buran
http://www.ariva.de/forum/Kontakt-508620?new_pnr=18779196#bottom
26.12.14 08:52
#68
buran
Dez. news klick
http://www.ariva.de/news/...-S-Partnership-for-PA8140-PA32540-5228196 GrB
26.12.14 08:53
#69
buran
17-12 in the news
http://www.ariva.de/news/...lete-Response-Letter-from-The-FDA-5242101 GrB
14.02.15 21:18
#70
buran
POZEN Announces Issuance
of VIMOVO® Related Patent by the United States Patent and Trademark Office
22:10 04.02.15
CHAPEL HILL, N.C. --(BUSINESS WIRE)-- http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283
22:10 04.02.15
CHAPEL HILL, N.C. --(BUSINESS WIRE)-- http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283
14.02.15 21:19
#71
buran
#70 POZEN Inc. (NASDAQ: POZN),a pharmaceutical
company committed to transforming medicine that transforms lives, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled “Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer” that relates to VIMOVO® (naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin. The patent expires in October 2031. http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283
14.02.15 21:20
#72
buran
#71 "This newly issued patent provides
“This newly issued patent provides additional claims to the VIMOVO patent estate,” stated John R. Plachetka, Chairman, President and Chief Executive Officer. “This patent further demonstrates the continued pattern of innovation by POZEN, which has resulted in 17 issued U.S. Patents and many related foreign patents.” http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283
14.02.15 21:21
#73
buran
#71 zu #72
“This newly issued patent provides additional claims to the VIMOVO patent estate,” stated John R. Plachetka, Chairman, President and Chief Executive Officer. “This patent further demonstrates the continued pattern of innovation by POZEN, which has resulted in 17 issued U.S. Patents and many related foreign patents.” http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283
..besser Inglisch with the Satzstellung ..nä ..::hopshops
..besser Inglisch with the Satzstellung ..nä ..::hopshops
14.02.15 21:23
#74
buran
mensch buran hör uff zu rumpeln
..kommt man ja reinewech und durchenander ..ey
14.02.15 21:24
#75
buran
schön Gruss an Willi Schwabe #74
zum Orbit Rasthof Steigerwald und seine Rumpelkammer ..geile Kellnerin Du ..datt Willichen nä ..hee hee ..unddd SDROWJE
buran
buran
3